Sorry, no content matched your criteria.
Featured Story
Biogen Idec (Nasdaq: BIIB) Stock Gains on FDA Approval of New MS Drug
Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.
The stock is up 14% in the last month and is still showing bullish signs.
Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.
The stock is up 14% in the last month and is still showing bullish signs.